Breast Cancer Bank of Tissue From Trial Assigning Individualized Options for Treatment (TAILORx Tissue Bank)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Cancer Trials Ireland
- Enrollment
- 600
- Locations
- 12
- Primary Endpoint
- Disease relapse, endocrine and/or chemotherapy resistance prognosis
Study Overview
Brief Summary
This is an exploratory, translational, non-interventional and multi-centre biobank. The aim of the development of such a biobank is to identify potential biomarkers that are indicative of disease relapse.
Detailed Description
The primary objective is to develop a biobank, tissue microarrays (TMAs) and full face sections, which will be used to identify candidate/ novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance.
The secondary objectives are:
- To validate emerging signatures/biomarkers identified.
- To develop new assays for the breast cancer clinic.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients that were registered with the ICORG 06-31 TAILORx trial and participated in trial arms
- •Patients with adequate tumor tissue available
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Disease relapse, endocrine and/or chemotherapy resistance prognosis
Time Frame: For duration of follow up, expected 10 years
A biobank, TMAs and full face sections, will allow for the identification of candidate/novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance
Secondary Outcomes
- Signature/biomarkers(For the duration of follow up, expected 10 years)